Nicholas Investment Partners LP lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,000 shares of the pharmaceutical company’s stock after buying an additional 214 shares during the quarter. Nicholas Investment Partners LP’s holdings in Vertex Pharmaceuticals were worth $4,253,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in VRTX. US Bancorp DE raised its stake in shares of Vertex Pharmaceuticals by 104.9% during the 1st quarter. US Bancorp DE now owns 7,324 shares of the pharmaceutical company’s stock worth $801,000 after buying an additional 3,749 shares during the period. Sei Investments Co. raised its stake in shares of Vertex Pharmaceuticals by 2.8% during the 1st quarter. Sei Investments Co. now owns 66,016 shares of the pharmaceutical company’s stock worth $7,218,000 after buying an additional 1,817 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $470,000. HL Financial Services LLC raised its stake in shares of Vertex Pharmaceuticals by 13.3% during the 1st quarter. HL Financial Services LLC now owns 3,440 shares of the pharmaceutical company’s stock worth $376,000 after buying an additional 405 shares during the period. Finally, Trexquant Investment LP raised its stake in shares of Vertex Pharmaceuticals by 374.3% during the 1st quarter. Trexquant Investment LP now owns 16,600 shares of the pharmaceutical company’s stock worth $1,815,000 after buying an additional 13,100 shares during the period. 92.85% of the stock is owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on VRTX. Raymond James Financial, Inc. raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 target price for the company in a research note on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. increased their price objective on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research note on Tuesday, July 4th. Finally, CIBC raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday, June 2nd. Six analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $163.35.

In other news, CMO Jeffrey Chodakewitz sold 573 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $129.85, for a total transaction of $74,404.05. Following the sale, the chief marketing officer now directly owns 123,084 shares in the company, valued at approximately $15,982,457.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paul M. Silva sold 2,577 shares of the stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $133.36, for a total value of $343,668.72. Following the sale, the senior vice president now owns 22,648 shares in the company, valued at $3,020,337.28. The disclosure for this sale can be found here. Insiders have sold 526,092 shares of company stock worth $84,101,702 in the last 90 days. 1.80% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-nicholas-investment-partners-lp/1573505.html.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.39% during midday trading on Tuesday, hitting $152.61. The stock had a trading volume of 336,646 shares. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The stock has a 50 day moving average of $154.56 and a 200-day moving average of $128.12. The company has a market cap of $38.48 billion, a P/E ratio of 146.60 and a beta of 1.75.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm had revenue of $544.10 million for the quarter, compared to analysts’ expectations of $489.95 million. During the same quarter in the prior year, the firm posted $0.24 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 26.1% compared to the same quarter last year. Analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.